Key Takeaways
- Resilient quarter despite textile drag: EBITDA grew ~26% YoY ex-one-offs, driven by the second contract ramp-up and value-added product mix, even as discretionary end-uses like textiles and dyes stayed weak.
- FY23 EBITDA guidance held, but FY24 flagged as turbulent: Management is not revising the ~₹1,100 crore FY23 target, but warned that a 2-3 quarter demand slowdown and contract one underperformance make FY24 a transition year.
- Nitric Acid sourcing deal frees up capital: A 20-year, ₹8,000+ crore supply agreement with Deepak Fertilisers eliminates a ₹200 crore captive plant investment, de-risks single-plant dependency, and redirects cash toward value-added chemistries.
- Margin uplift is a post-FY25 story: The real shift toward higher-margin, value-added products begins only from FY25, so the 25% EBITDA CAGR target is back-end loaded and depends on new capacities commissioning on time.
- What to watch next quarter: FY24 volume and margin clarity promised in Q4, the pace of contract one’s upstream redirection into alternative markets, and any stabilization in textile and agrochemical end-demand.
Demand & End-Market Conditions
- Textiles remained the weakest link: A global demand slowdown, high inflation, and country-specific troubles in Bangladesh and Turkey have pressured the textile end-use segment for several quarters, with the domestic textile portion (15-20% of sales) effectively flat on a 9-month basis.
- Discretionary categories under pressure: The dye side of the discretionary portfolio saw some impact, though other discretionary areas held up in Q3; management noted recessionary trends now becoming visible in segments like auto as well.
- Agrochemical demand is molecule-specific: Some molecules are seeing inventory correction, but the impact is not expected to last more than a quarter for certain products, not all.
- China demand normalized: After restrictions were lifted, demand from China has returned to normal levels overall.
- Export markets softening: Some decline in the regular export market is visible, requiring product reshaping; some export demand impact is expected in coming quarters.
- Domestic volumes likely negative: 9-month sales growth of ~₹860 crore was entirely export-driven; with commodity prices up, domestic volume growth could have been negative, though management reshuffles products across markets to optimize.
Rajendra Gogri: "General slowdown, that we see from the customer end and everything, that can last about next 2 to 3 quarters, I think that is the broader feedback what we are getting from the customer side."
Long-Term Contracts: Progress & Problems
- Second contract fully ramped up: The second long-term contract has reached full run-rate and was a key contributor to the ~26% ex-one-off EBITDA growth; the associated customer advance will phase out gradually over more than 3 years, at a rate a bit lower than 20-25% per year.
- Third contract plant commissioned: The plant at Jhagadia was commercialized by end-Q3 FY23; no meaningful contribution is expected in Q4, with ramp-up beginning from Q1 FY24 per contract terms.
- Contract one (Dicamba intermediate) struggling: Downstream demand for the end-product remains slow; a shutdown was taken in Q3; utilization is at 30-40%, and the earlier FY24 guidance of 70% utilization may not materialize.
- Contract one strategy under review: Management is evaluating whether to go downstream or convert the second production line to other products; upstream precursors are being redirected to other markets and are expected to ramp to near-full utilization over the next two years.
- Volume strategy carries a margin trade-off: To sustain volumes, some products may be placed into non-regular markets that tend to offer lower margins, a deliberate choice to keep capacity utilized while regular demand is soft.
Rajendra Gogri: "Currently basically, we are looking at slowdown in that even FY24, we don't expect that what we have guided 70% may not happen, so overall we are evaluating under our strategy on that whether we can go downstream or we can try to convert the other line into some other products where we have two different lines in that."
Margin & Profitability Drivers
- Value-added mix supported Q3 profitability: The share of value-added products was about 81% in Q3, and higher share from these products drove better profitability despite demand weakness in some end-user categories.
- Sequential EBITDA margin expansion explained: Q2 had a maintenance shutdown that inflated expenses; that partly corrected in Q3, aided by some volume growth and expense savings; raw material and freight costs are generally pass-through, but the savings portion contributed to EBITDA and is retainable.
- Real margin uplift is post-FY25: Value-added product sales will start mainly from FY25; the percentage share of higher-margin products will rise gradually, and overall gross margin at constant raw material will increase beyond FY25.
- New projects targeted at 25%+ margins: Newer projects are likely to have a margin profile of 25% plus, supporting the medium-term profitability trajectory.
- Fixed cost leverage from FY24: As volume growth from new capacities materializes over the coming two years, fixed costs will generally tail macro inflation, yielding robust gross-profit-to-EBITDA conversion starting FY24.
Rajendra Gogri: "Actually, the value-added product sales will be starting mainly from FY25. So, the impact of the high margin will be coming post FY25. So, slowly the percentage share of this high, more value-added product goes up and overall gross margin at the constant raw material will increase beyond FY25."
Capex & Capacity Expansion
- FY24-FY25 capex target unchanged at ~₹3,000 crore: Aimed at developing new chemical value-chains and introducing high-potential products; the collective target stands.
- Near-term commissioning timeline: Except Nitrotoluene and Ethylation, most projects will be commissioned by H1 FY24; Nitrochlorobenzene and some Specialty Chemical blocks are currently under construction and will become operational in the next couple of quarters, contributing from H2 FY24.
- Ethylation and Nitrotoluene on track for H1 FY25: Ethylation capacity at Dahej SEZ is being expanded 3x with a ₹200 crore investment; Nitrotoluene debottlenecking targets a ~50% capacity increase; both expected to commercialize in H1 FY25.
- Chlorotoluene and Multipurpose Plants are FY25-FY26 stories: Chlorotoluene involves multiple blocks commissioning over FY25 and FY26; the Multipurpose Plant will commission in FY25; real EBITDA contribution from these new products will come from FY26, not much in FY25.
- Nitric Acid backward integration dropped: The decision to source from Deepak Fertilisers under a 20-year binding agreement eliminates the need for a ₹200 crore captive Concentrated Nitric Acid plant, de-risking single-plant dependency and freeing cash flow for specialized chemistries.
Rajendra Gogri: "It is kind of de-risk us rather than having one single stream plant for us. That is an advantage of sourcing from Deepak Fertilisers compared to our own single plant dependency and second thing, it frees up the cash flow for more on value-added specialized chemistries."
Growth Outlook & Structural Themes
- 25% EBITDA CAGR (FY23-FY25) stands, but back-end loaded: Growth is more skewed toward FY25; FY24 is expected to be a turbulent year with slowdown continuing for 1-2 quarters; management will provide clarity in Q4.
- FY25 revenue target: Targeting ₹1,700 crore EBITDA by FY25, implying revenue upward of ₹8,500 crore at a ~5x multiple.
- Medium-term volume growth of 40-50% on existing lines: The 25% EBITDA CAGR is largely volume-driven from existing segments; new products (Chlorotoluene, etc.) contribute meaningfully only from FY26.
- China Plus One is a 5-10 year structural tailwind: The trend has been ongoing for 5-7 years and is expected to continue for the next 5-10 years, supporting long-term demand for Indian specialty chemical players.
- Europe Plus One is a 2-3 year opportunity: Energy-intensive products may see reduced investment in Europe as energy costs rise, opening opportunities for India; identifying products and building capacity will take 2-3 years, with only discussions underway currently.
- R&D pipeline of 50+ products: Commissioning from FY25 onwards, forming the next wave of growth beyond the current expansion cycle.
Rajendra Gogri: "FY24 is I think will be more of a turbulent year in that sense. So, that clarity we will be able to give in Q4."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 EBITDA | ~₹1,100 crore; not revising, will reshuffle products to meet target | FY23 |
| FY24-FY25 EBITDA CAGR | 25% CAGR, based on solid business visibility | FY24-FY25 |
| FY25 EBITDA target | ₹1,700 crore, implying revenue upward of ₹8,500 crore | FY25 |
| FY24-FY25 collective capex | ~₹3,000 crore | FY24-FY25 |
| Ethylation & NT commercialization | Both units expected to commercialize | H1 FY25 |
| Near-term project commissioning | Except NT and Ethylation, most projects commissioned | H1 FY24 |
| Contract one upstream ramp-up | Upstream precursors redirected to other markets, ramp to near-full utilization | Next 2 years |
| Contract two advance phase-out | More than 3 years, annual phase-out a bit lower than 20-25% | 3+ years |
| Tax rate | Expected to remain lower than 20% | Ongoing |
| Year-end debt | Expected around ₹2,600-2,700 crore | FY23 |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹1,854 cr, +12% YoY; exports contributed over 48% of total revenues |
| EBITDA | ₹289 cr, +26% YoY |
| Profit after tax | ₹137 cr |
| EBITDA margin | 15.6%, up from 13.9% in Q3 FY22 (per an analyst's math) |
| Value-added product share | 81% of total revenue |
| 9M FY23 EBITDA | ₹837 cr, against full-year guidance of ~₹1,100 cr |
| FY24–FY25 EBITDA CAGR guidance | 25%, volume-driven from existing product lines; skewed towards FY25 |
| 9M FY23 capex | ₹840 cr; full-year target ₹1,100–1,200 cr |
| FY24–FY25 collective capex target | ₹3,000 cr |
| FY25 EBITDA target | ₹1,700 cr |
| Nitro chlorobenzene production | 18,199 MT |
| Nitro-Toluene production | 7,528 MT; capacity utilization over 90% |
| Hydrogenation production | 2,995 TPM |
| Interim dividend | ₹1 per share, 20% of face value of ₹5 |
| Gross debt (year-end expected) | ₹2,600–2,700 cr, gross and net similar |